ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1280

Generation of Evidence Supporting the Content Validity of SF-36, Lupus-Qol, and FACIT-Fatigue, and Newly Developed Patient-reported Outcome (PRO) Symptom Items to Address Conceptual Gaps for Use in Patient with Lupus Nephritis

Rebecca Hall1, Nicola Williamson1, Melissa Barclay1, Anna Roberts1, Adam Gater1, Chloe Tolley1, Helena Bradley1, Amy Ward1, Patricia Delong2, Elizabeth Hsia3, Qing Zuraw4, Zahi Touma5, Vibeke Strand6 and Pamela Berry2, 1Adelphi Values Ltd, Bollington, United Kingdom, 2Janssen Global Services, LLC, Horsham, PA, 3Janssen Research & Development, LLC, Spring House, PA, 4Janssen R&D, Wayne, PA, 5University of Toronto, Mississauga, ON, Canada, 6Stanford University School of Medicine, Portola Valley, CA

Meeting: ACR Convergence 2021

Keywords: Lupus nephritis, Qualitative Research, quality of life, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 8, 2021

Session Title: SLE – Diagnosis, Manifestations, & Outcomes Poster III: Outcomes (1257–1303)

Session Type: Poster Session C

Session Time: 8:30AM-10:30AM

Background/Purpose: Lupus nephritis (LN) is an autoimmune disease characterized by inflammation of the kidneys, a severe manifestation of systemic lupus erythematosus (SLE) that occurs in approximately 50% of SLE patients. To evaluate treatment benefit effectively, it is critical that patient-reported outcome (PRO) measures are fit-for-purpose and have strong evidence of content validity in the specific context of use, to serve as trial endpoints and support product label claims. SF-36, Lupus-QoL, and FACIT-Fatigue are commonly used clinical trial endpoints in SLE populations, with demonstrated evidence of content validity in this population. Similar evidence of their content validity in an LN population is lacking. A prior qualitative literature and online blog review and concept elicitation interviews with LN patients identified key symptoms (i.e., skin rash, joint pain, joint stiffness, and swelling of the legs/feet) and symptom properties (i.e., severity) not adequately assessed by these three PRO measures. Novel PRO symptom severity items were developed to address conceptual gaps. This study aimed to evaluate the content validity of SF-36, Lupus-QoL, FACIT-Fatigue, and novel PRO items in a sample of LN patients.

Methods: Qualitative, semi-structured, telephone cognitive interviews were conducted with 20 US adult patients with a diagnosis of LN. To evaluate the content validity of the existing PRO measures, participants’ understanding and relevance of the concepts to their experience of LN was assessed. Participants completed the novel PRO items using a ‘think aloud’ process. Questioning explored understanding and relevance of item wording, instructions, different recall periods (24-hour vs 7-day), and response scales (numeric rating scale (NRS) vs verbal response scale). Interviews were conducted in two rounds to allow for modifications to novel PRO items and subsequent re-testing. Qualitative analysis of verbatim interview transcripts was performed.

Results: Symptom and impact concepts assessed by SF-36, Lupus-QoL, and FACIT-Fatigue were well understood, with most considered relevant by the majority of participants asked. Symptoms assessed by the novel PRO items were considered relevant to most participants. Participant feedback informed modifications to the novel PRO items and instructions to improve clarity and understanding between rounds. Each iteration of the item wording and instructions were understood and interpreted consistently by all participants asked. The selected 7-day recall period and NRS in the final iteration of the PRO items were understood, relevant, and appropriately endorsed.

Conclusion: Findings support the content validity of the symptom and impact concepts assessed by SF-36, Lupus-QoL, FACIT-Fatigue in LN patients, providing evidence of their suitability as supportive efficacy endpoints in LN randomized controlled trials. Content validity evidence was also generated for the novel PRO items in LN patients, supporting their suitability to address conceptual gaps in existing PRO measures. Further research is required to establish the psychometric validity of the novel PRO items in a LN population.


Disclosures: R. Hall, None; N. Williamson, Janssen, 2; M. Barclay, None; A. Roberts, None; A. Gater, None; C. Tolley, None; H. Bradley, None; A. Ward, None; P. Delong, Janssen, 3, 11; E. Hsia, Janssen Research & Development, LLC (a subsidiary of Johnson & Johnson), 3, 11; Q. Zuraw, Johnson & Johnson, 3, 11, Johnson & Johnson, 3, 11; Z. Touma, AbbVie Inc, 2, UCB Biopharma SRL, 2, Sarkana Pharma Inc., 1, 4, Janssen Inc., 2, GlaxoSmithKline Inc., 6; V. Strand, Abbvie, 2, Amgen, 2, Genentech / Roche, 2, Janssen, 2, Novartis, 2, Pfizer, 2, Sanofi, 2, UCB, 2, Bristol-Myers Squibb, 2, Boehringer Ingelheim, 2, Celltrion, 2, Arena, 2, Gilead, 2, GlaxoSmithKline, 2, Ichnos, 2, Inmedix, 2, Kiniksa, 2, Merck, 2, Myriad Genetics, 2, Regeneron Pharmaceuticals, Inc., 2, Samsung, 2, Sandoz, 2, Setpoint, 2, Galapagos, 2, Horizon, 2, Lilly, 2, Rheos, 2, R-Pharma, 2, Scipher, 2, Sun Pharma, 2; P. Berry, Janssen Global Services LLC, 3, 11.

To cite this abstract in AMA style:

Hall R, Williamson N, Barclay M, Roberts A, Gater A, Tolley C, Bradley H, Ward A, Delong P, Hsia E, Zuraw Q, Touma Z, Strand V, Berry P. Generation of Evidence Supporting the Content Validity of SF-36, Lupus-Qol, and FACIT-Fatigue, and Newly Developed Patient-reported Outcome (PRO) Symptom Items to Address Conceptual Gaps for Use in Patient with Lupus Nephritis [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/generation-of-evidence-supporting-the-content-validity-of-sf-36-lupus-qol-and-facit-fatigue-and-newly-developed-patient-reported-outcome-pro-symptom-items-to-address-conceptual-gaps-for-use-in-pa/. Accessed February 4, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/generation-of-evidence-supporting-the-content-validity-of-sf-36-lupus-qol-and-facit-fatigue-and-newly-developed-patient-reported-outcome-pro-symptom-items-to-address-conceptual-gaps-for-use-in-pa/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences